Monitor for any conversion of the pre-funded warrant (subject to 9.99% blocker) and for potential future 13G amendments if General Atlantic increases its position. The passive filing suggests no near-term activist pressure, but the large stake provides a credible institutional backstop ahead of Phase 1 data for KRSA-028 expected mid-2027.
Price Chart
Executive Summary
General Atlantic, L.P. and affiliated entities filed a Schedule 13G disclosing a 6.8% passive stake in Korsana Biosciences (KRSA), consisting of 1,366,242 shares and a pre-funded warrant for 1,834,889 shares. This filing follows the company's recent reverse merger (completed September 8, 2026) and $380M PIPE, where General Atlantic was likely a PIPE participant. The passive filing indicates no activist intent, but the sizable stake signals conviction in Korsana's Alzheimer's pipeline (KRSA-028) post-merger.
Key Financial Metrics
Key Facts
- General Atlantic and affiliates beneficially own 3,201,131 shares (6.8%) of Korsana Biosciences common stock as of September 8, 2026.
- The stake includes 1,366,242 shares held directly by General Atlantic (KB), L.P. and a pre-funded warrant to purchase 1,834,889 shares.
- The percentage is based on 47,376,314 shares outstanding (including 1,834,889 shares issuable upon exercise of the pre-funded warrant).
- The filing is a passive Schedule 13G (Rule 13d-1(d)), indicating no intent to influence or control the company.
- This filing follows the company's reverse merger with Korsana (formerly Cyclerion Therapeutics) on September 8, 2026, and a concurrent $380M PIPE.
Financial Impact
General Atlantic holds a 6.8% passive stake valued at approximately $3.2 million based on 3,201,131 shares (no per-share price disclosed in filing).
Risk Factors
- General Atlantic's passive stance could shift if the company underperforms, potentially leading to a 13D conversion or stake reduction.
- The pre-funded warrant's 9.99% blocker limits near-term dilution but could be amended, increasing overhang.
- Korsana is a pre-revenue biotech with no approved products; clinical trial failure of KRSA-028 would significantly impact valuation.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000950142-26-002568 |
| Document: eh260831556_scha.htm | 0000950142-26-002568 |
| Document: 0000950142-26-002568-index-headers.html | 0000950142-26-002568 |
| Document: 0000950142-26-002568-index.html | 0000950142-26-002568 |
| Document: 0000950142-26-002568.txt | 0000950142-26-002568 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 144 | $31.31 | awaiting T+20 | — | $32.09 (+2.49%) |
Oct 15, 2026 12d ago | SC 13G/A | $32.38 | awaiting T+20 | — | $32.09 (−0.90%) |
Oct 15, 2026 12d ago | DEF 14A | $32.38 | awaiting T+20 | — | $32.09 (−0.90%) |
Sep 23, 2026 4w ago | 144 | $37.19 $33.43 | ▼ −10.11% | ▼ −9.69% | $32.09 (−13.71%) |
Sep 22, 2026 5w ago | 144 | $32.30 $32.54 | ▲ +0.74% | ▲ +0.06% | $32.09 (−0.65%) |
Sep 18, 2026 5w ago | SC 13G | $33.21 $31.41 | ▼ −5.42% | ▼ −4.51% | $32.09 (−3.37%) |
Sep 18, 2026 5w ago | 144 | $33.21 $31.41 | ▼ −5.42% | ▼ −4.51% | $32.09 (−3.37%) |
Sep 16, 2026 5w ago | SC 13G | $31.23 $34.32 | ▲ +9.89% | ▲ +7.83% | $32.09 (+2.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers